Dry skin (xerosis)
Also known as: Xerosis
Methodology & AI Transparency ⓘ
Dry skin (xerosis) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code L85.0 in Skin & Dermatology, Dry skin (xerosis) (also termed Xerosis) requires dermoscopy or punch in Dry skin (xerosis) (L85.0: biopsy when atypical) so specialists can calibrate treatment intensity against 25-Hydroxy Vitamin D in Dry skin (xerosis) (L85.0: & hs-CRP) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry L85.0: Dry skin (xerosis) is managed within Skin & Dermatology (aka Xerosis).
- 3 Typical cash cost range: Clinicians assessing Dry skin (xerosis) focus on cutaneous immune skewing in Dry skin (xerosis) (L85.0: (Th2/IL-4/IL-13 in atopic) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Dry skin (xerosis) monitoring tracks 25-Hydroxy Vitamin D in Dry skin (xerosis) (L85.0: & hs-CRP) toward 25(OH)D 40–65 ng/mL (L85.0).
Ask our AI Specialists anything about Dry skin (xerosis)
What Is Dry skin (xerosis)?
Cataloged under federal diagnostic code L85.0 in Skin & Dermatology, Dry skin (xerosis) (also termed Xerosis) requires dermoscopy or punch in Dry skin (xerosis) (L85.0: biopsy when atypical) so specialists can calibrate treatment intensity against 25-Hydroxy Vitamin D in Dry skin (xerosis) (L85.0: & hs-CRP) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
In Dry skin (xerosis) (L85.0), physiological disruption stems from cutaneous immune skewing in Dry skin (xerosis) (L85.0: (Th2/IL-4/IL-13 in atopic), informing Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols that track Affected Body Surface in Dry skin (xerosis) (L85.0: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (L85.0)).
Common Symptoms & Clinical Signs
- • Presentation of Dry skin (xerosis) (L85.0): compromised epidermal barrier in Dry skin (xerosis) (L85.0: with dryness, fissuring,)
- • Secondary Dry skin (xerosis) clinical sign: post-inflammatory hyperpigmentation, facial in Dry skin (xerosis) (L85.0: flushing, or pitted)
- • Symptom flares in Dry skin (xerosis) correlating with 25-Hydroxy Vitamin D in Dry skin (xerosis) (L85.0: & hs-CRP) deviation outside 25(OH)D 40–65 ng/mL (L85.0)
- • Functional skin & dermatology impact requiring dermoscopy or punch in Dry skin (xerosis) (L85.0: biopsy when atypical) evaluation (L85.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Dry skin (xerosis) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L85.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Dry skin (xerosis) (L85.0: & hs-CRP) | 25(OH)D 40–65 ng/mL (L85.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Dry skin (xerosis) (L85.0: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L85.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Dry skin (xerosis) (L85.0: ALT (if systemic) | Within baseline reference limits (L85.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Dry skin (xerosis)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Ammonium Lactate Lac-Hydrin • RxCUI 197362 | alpha-Hydroxy Acid | 78% | $0.0624 | $ 12.02 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dry skin (xerosis))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients: What a 1,614-Participant Study Found Once-daily treatment with tazarotene 0.045% polymeric emulsion lotion may help improve patient-perceived skin oiliness in those with moderate-to-severe acne. The Journal of dermatological treatment • 2023-12-15 • Randomized Controlled Trial | N = 1,614 | 96/100 | PMID 36382987 ↗ |
| New Insights on Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy: What a 1,564-Participant Study Found The diagnostic performance of the EC skin test was similar to that of the T-SPOT test in the healthy population and was unaffected by BCG vaccination. BMC infectious diseases • 2024-12-30 • Phase III Randomized Trial | N = 1,564 | 96/100 | PMID 39736611 ↗ |
| New Insights on Incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic: What a 259-Participant Study Found The incidence of TD was relatively low in both younger and older patients with depression with psychotic features treated acutely with olanzapine. Journal of clinical psychopharmacology • 2013-06-15 • Randomized Controlled Trial | N = 259 | 93/100 | PMID 23609383 ↗ |
| New Insights on Psychometric evaluation of the Worst severe itching Numerical Rating Scale (NRS),: What a 769-Participant Study Found These results provide evidence that the scores produced by the Worst severe itching NRS, ADerm-SS, and ADerm-IS are reliable and construct-valid when completed by adults and adolescents with moderate to severe AD in a clinical... Current medical research and opinion • 2023-10-15 • Phase III Randomized Trial | N = 769 | 93/100 | PMID 37691437 ↗ |
| New Insights on Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute: What a 335-Participant Study Found TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-10-05 • Phase III Randomized Trial | N = 335 | 93/100 | PMID 32897367 ↗ |
Dry skin (xerosis) Patient Community & “People Like Me” Threads
Filter Dry skin (xerosis) community threads and patient logs by age, biological sex, dosage, and treatment duration.